Published January 17, 2024

License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness

Dublin, Ireland, and Tampere, Finland, 17 January 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell-based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio.

StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for unmet medical needs in corneal blindness. Led by a team of expert scientists in the field of stem cells and tissue engineering for eye applications, StemSight originated as a spin-out from pluripotent stem cell pioneer Prof Heli Skottman’s laboratory at Tampere University. StemSight is at the forefront of innovative research in regenerative medicine of the cornea.

Dr Laura Koivusalo, CEO and Co-founder of StemSight, said: “This partnership with ERS Genomics is a significant leap forward for StemSight. By harnessing the remarkable capabilities of CRISPR/Cas9 we will be able to address major challenges of the current allogeneic cell therapies, ultimately bringing us closer to life-changing therapies for patients with currently incurable blindness.”

Eric Rhodes, CEO of ERS Genomics, commented: “We are pleased to add StemSight to our family of licensees. This collaboration underscores the growing prominence of Finland, and the Nordics, in the global biotechnology and life science sector. StemSight’s use of CRISPR/Cas9 technology to develop regenerative therapies that will change the lives of patients suffering from limbal stem cell deficiency is truly pioneering.”

StemSight

You may also like…

Contact us share your movers & shakers news

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!